Ema inspection process


Published on

  • Be the first to comment

No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide

Ema inspection process

  1. 1. The EMA Inspection Process Procedures, Timelines & Expectations Presented by Vaska Toné
  3. 3. GCP Inspections  Systems Inspections ● Look at all relevant SYSTEMS for CTIMPs o CTIMP = Clinical Trial of Investigational Medicinal Product ● Check that the expected process is used in practice  Study Specific Inspections ● Carefully review the study data ● Is it real, reliable and trustworthy? ● Reduced reliance on interviews ● But site staff will/may be interviewed 3
  4. 4. Inspection Reason Mainly based on questions raised by assessors reviewing the submitted dossier But can be caused by intelligence obtained relating to potential problems within clinical trials EMA has no inspectors – they “subcontract” inspecting to the individual member states to perform the inspection according to the EMA SOPs Each member state has its own inspectorate and inspects in its own territory independently 4
  5. 5. EMA Definitions  Reporting Inspectorate (RI) ● The inspectorate member state designated by the EMA to manage the inspection and timelines and writing the Integrated Inspection Report  Reporting Inspector ● The Inspector at the RI with responsibility for the inspection  Lead Inspector (LI) ● The inspector leading the conduct of an inspection and writing the Inspection Report. The LI is based in the member state where the inspection is performed 5
  6. 6. EMA Definitions  Inspection Report (IR) ● The report produced after each site inspection by the Lead Inspector. Should responses not be provided in the expected timeframe this fact is documented in the report by the LI.  Integrated Inspection Report (IIR) ● Prepared by the RI based on each of the IRs for the whole inspection. Contains an evaulation of the quality of the data and GCP compliance. Signed by all LIs who have written IRs for the overall inspection. Includes recommendations for follow-up and further inspections 6
  7. 7. EMA Inspections  EMA has no inspectors – they “subcontract” inspecting to the individual EU member states to perform the inspection according to the EMA SOPs  Each member state has its own inspectorate and inspects in its own territory independently  All EMA procedures are documented and in the public domain 7
  8. 8. EMA Procedures  All EMA procedures are documented and in the public domain  Located on the EMA website under: o EMA Home Regulatory → Human Medicines → Inspections → GCP Compliance → Inspections Procedure http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulatio  This documents all the EMA SOPs relating to GCP inspection processes  Each SOP can be opened and is readable 8
  9. 9. EMA Procedures 9
  10. 10. EMA Procedures 10
  11. 11. EMA Timelines 11
  12. 12. Dossier  Dossier request – usually 30 days prior to inspection • Can be very helpful to get to know your own company better and for QA to be “In the Loop” • Takes a long time to complete with participation of many departments • Listing of systems in use for the trials and those outsourced • List of trials taken place over a period of years • Plan – inspector prepares with input from the inspectee • Studies are pre-selected by the inspectors • Generally more than one study selected 12
  13. 13. Dossier  Dossier Details: There are 2 sections that need to be completed: • Section 1 has 6 required items to be provided: • Item 1: Organizational Charts • Item 2: List of Clinical Trial Processes (SOPs, etc) • Item 3: Adverse Event Reporting Systems & Procedures • Item 4: List of Computer Systems & Validation Status • Item 5: For non-commercial organizations only • Item 6: List of clinical trials (use the provided spreadsheet) 13
  14. 14. Dossier  Section 2 has 3 items: • Item 1 & 2: Names and addresses of all facilities involved in the clinical trials, including: o Vendors (i.e. labs, drug depots) o CROs (full scope, niche i.e.: DM, Stats, Safety) o Support services (readers: ECG, CT/MRI/Bone Scan imaging, etc) 14
  15. 15. Dossier  Section 2 has 3 items: • Item 3: Summary information of your organization’s clinical trial systems (info on 1 side of paper for each department) 1. Contract and Agreement Preparation 2. Quality System (including training) 3. Clinical Quality Assurance 4. Project Management 5. Clinical Trial Monitoring 6. Pharmacovigilance (including medical expertise) 7. Regulatory Affairs 8. Computer Systems 15
  16. 16. Dossier  Item 3 continued: 9. Investigational Medicinal Products (IMP) 10. Data Management & Statistics 11. Clinical Trial Reporting 12. Trial Master File 13. Archiving 14. Clinical Facilities 15. Laboratories 16. Equipment Maintenance 16
  17. 17. Investigator Site Selection EMA • Can be selected by the EMA or the assessors of the data depending on the information and intelligence held about each investigator site • The inspectors may add in more or change the investigator sites after review of the data 17
  18. 18. Inspection Process • Usually site inspection AFTER the Sponsor/CRO inspection but NOT always • If the Inspection is based on a marketing application, more emphasis will be placed on data credibility and assurance that data exists and is true at the site • Less interview, more data review • CRA should be present to provide assistance to the inspectors • Documents may be requested during the inspection (requested using a request form) 18
  19. 19. Inspection Topics  System inspections • Look at any issues seen in monitoring visit reports • Issues with safety, data or site knowledge of GCP or the protocol • Not always the highest recruiter  Study Inspections • Depends on the issues that the assessor has noted within the submitted dossier • It may be an issue relating to credibility of site data • It may be a company data management issue • The investigator site provides the data so are key inspection areas for both types of inspection 19
  20. 20. Inspector Selection • Two member states present if EMA requested, the host member state plus one other member state • The lead inspector will contact the site to arrange the dates for the inspection • But the dates need to be acceptable to both member states attending the inspection 20
  21. 21. General Inspection Process • Review of documentation and interview with staff members • Interviews can be by video/telecon if necessary • Documents will be requested using a request form • Further unannounced studies can be requested • Review of areas where the research is managed • Inspectors can go “off-plan” if there is a need 21
  22. 22. On Site Inspection Conduct • Inspection hours – from 9am to 5pm but can be longer if necessary • Opening meeting – to explain the purpose of the inspection • Inspected company provides a SHORT relevant presentation to the inspectors • Have ALL requested documentation ready from the beginning 22
  23. 23. Expectations & Close Out • Document review sessions – leave the inspectors alone unless they request assistance • Don’t offer more info than necessary – if TMF is paper leave it at that, if you have online access to it, the inspector will want the same • Inspectors closed meeting to collate findings and prepare for closing • Closing meeting o to provide the observations noted and the grading of those observations o to inform inspectee of the selected investigator sites 23
  24. 24. Any Questions? 24
  25. 25. LaVaPharm Consulting 25 Vaska Tone President & CEO LaVaPharm Consulting LLC Email: vaska.tone@lavapharm.com US Office Phone: +1-951-240-5635 European Office: +389-75-417-417